KNSA250117C22500
- 1.25
- 0.000.00%
Kiniksa Pharmaceuticals International Newsroom
Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $357,680, According to a Recent SEC Filing
US Manufacturing Index Rises To 43, Highest Since 2020
Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference
J.P. Morgan Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $40
Kiniksa Pharmaceuticals International, Plc Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
Kiniksa Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
Kiniksa Pharmaceuticals Analyst Ratings
Evercore Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $35
Kiniksa Pharmaceuticals International | 10-Q: Q3 2024 Earnings Report
Kiniksa Pharmaceuticals Shares Are Trading Lower After the Company Announced Worse-than-expected Q3 Financial Results.
Kiniksa Pharmaceuticals International, Plc (KNSA) Q3 2024 Earnings Call Transcript Summary
Kiniksa Pharmaceuticals International, Plc (KNSA) Q3 2024 Earnings Call Transcript
Kiniksa Pharmaceuticals Down Over 12%, on Pace for Largest Percent Decrease Since August 2021 -- Data Talk
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates
Kiniksa Pharmaceuticals International | 8-K: Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution
Kiniksa Pharmaceuticals Q3 2024 GAAP EPS $(0.18) May Not Be Comparable To $0.04 Estimate, Sales $112.21M Beat $111.52M Estimate
Kiniksa Expects to Remain Cash Flow Positive on Annual Basis >KNSA
Kiniksa: ARCALYST 2024 Expected Net Pdt Rev Increased to $410 M - $420 M >KNSA
Express News | Kiniksa Pharmaceuticals Ltd: Expects 2024 Arcalyst Net Product Revenue of Between $410 Mln and $420 Mln